Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Raises $250M in Funding Round

NEW YORK (GenomeWeb) – 23andMe has raised $250 million in funding, the consumer genomics firm announced today.

23andMe said it plans to use the money to grow its customer base, expand its therapeutics group, and invest in its genetic research platform. With this latest funding, 23andMe has raised $491 million from a range of investors, including technology and health science companies, angel investors, and venture capital firms.

This funding round was led by Sequoia Capital and included Euclidean Capital, Altimeter Capital, and the Wallenberg Foundation, all new investors in 23andMe. Current investors Fidelity Management & Research Company and Casdin Capital also contributed funding.

Roelof Botha, partner at Sequoia Capital, will join 23andMe's board of directors. The firm also noted that Neal Mohan, chief product officer at YouTube and a senior VP at Google, joined the board in July. 

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.